ArticleFrontiers in cardiovascular medicine2025
Positive association between fibrinogen-to-albumin ratio and preeclampsia risk in pregnant women of advanced maternal age: implications for clinical risk assessment.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenotypic subclassification of preeclampsia through cluster analysis of preterm birth-related factors.BMC medical informatics and decision making · 2026Article
- Second-Trimester Fibrinogen-to-Albumin Ratio and Platelet Activation Markers Compared with the HALP Score for Predicting Preeclampsia.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Preeclampsia is a serious hypertensive disorder unique to pregnancy, with increased prevalence among women of advanced maternal age (AMA). Given the central role of inflammation and vascular dysfunction in the development of preeclampsia, this study aimed to evaluate the relationship between the fibrinogen-to-albumin ratio (FAR) multiplied by 100 (FAR × 100) and risk of preeclampsia in this high-risk group. Methods: A retrospective cohort of 2,296 pregnant women of advanced maternal age (≥35 years) was analyzed. The exposure variable, FAR × 100, was calculated as fibrinogen (g/L) divided by albumin (g/L) and multiplied by 100. PE was diagnosed based on the established clinical criteria. Participants were grouped into tertiles according to FAR × 100 levels. Both crude and adjusted logistic regression models were used to assess associations. Nonlinear relationships were assessed using restricted cubic spline (RCS) analysis, and subgroup analyses were conducted based on maternal characteristics. Results: The average age was 37.8 ± 2.7 years, with a preeclampsia prevalence of 14.3%. A higher FAR × 100 score was significantly associated with increased odds of developing preeclampsia. In the fully adjusted model, each unit increase in FAR × 100 raised the likelihood of preeclampsia by 8% (odds ratio [OR] = 1.08; 95% confidence interval [CI]: 1.06-1.10; Conclusion: FAR × 100 is independently associated with preeclampsia among women of AMA and may serve as a low-cost practical biomarker for early clinical risk stratification in prenatal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.